New Molecularly Targeted Therapeutic Approved for Ovarian Cancer
The FDA approved a molecularly targeted therapeutic for women with advanced ovarian cancer linked to a BRCA gene mutation.
Progress Against Cancer
The FDA approved a molecularly targeted therapeutic for women with advanced ovarian cancer linked to a BRCA gene mutation.
Results from two clinical trials highlight the benefits of the molecularly targeted therapeutics ceritinib and osimertinib.
A government report shows that among the top 10 causes of death in the United States, the death rate for cancer was the only one to decline in 2015.
Study reports that alcohol, particularly white wine, consumption may be associated with higher risk for melanoma.
In a study, researchers found that regular use of aspirin reduced pancreatic cancer risk by almost 50 percent.
A genetic biomarker may help identify breast cancer patients at increased risk for heart damage caused by anthracycline chemotherapy.
Researchers are using genetic tests to help identify breast cancer patients at risk for potentially life-threatening complications of chemotherapy. Blood clots that develop in the veins of patients – known as venous thromboembolism or...
The U.S. FDA decision to approve nivolumab for head and neck cancer means nivolumab is now an approved treatment for five types of cancer.
A recent study reports that how pediatricians talk to parents can affect whether or not they chose to have their child vaccinated against human papillomavirus (HPV). For pediatricians and parents of adolescents, across the...
Each of the three obesity-related factors, body mass index (BMI), waist size, and type 2 diabetes, was associated with liver cancer risk in a large study.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More